Hypoglycaemia induced by exogenous insullin - 'Human' and animal insulin compared

Diabetic Medicine

Volumn 17, Issue 6, 2000, Pages 416-432

  Airey, C M ^a   Williams, D R R ^a,c   Martin, P G ^b   Bennett, C M T ^a   Spoor, P A ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b CHURCHILL HOSPITAL   (United Kingdom)

^c NUFFIELD INSTITUTE FOR HEALTH   (United Kingdom)

Author keywords

Animal insulin; Diabetes mellitus; Human insulin; Hypoglycaemia; Systematic review

Indexed keywords

BOVINE INSULIN; HUMAN INSULIN; PIG INSULIN;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DOUBLE BLIND PROCEDURE; DRUG ACTIVITY; DRUG EFFICACY; HOSPITALIZATION; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; RANDOMIZED CONTROLLED TRIAL; REVIEW;

ANIMALS; AWARENESS; DIABETES MELLITUS; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; PERCEPTION; RANDOMIZED CONTROLLED TRIALS;

EID: 0033913842     PISSN: 07423071     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-5491.2000.00304.x     Document Type: Review

References (116)

1. 1 Home PD, Mann NP, Hutchison AS, Park R, Walford S, Murphy M et al. A fifteen-month double-blind cross-over study of the efficacy and antigenicity of human and pork insulins. Diabetic Med 1984; 1: 93-98.
2. 2 Zuppinger K, Aebi C, Fankhauser S, Herz G, Zurbrugg RP, Schopfer K et al. Comparison of human and porcine insulin therapies in children with newly diagnosed diabetes mellitus. Diabetologia 1987; 30: 912-915.
3. 3 Anonymous. Human insulins: an update. Drug Ther Bull 1989; 27: 21-24.
4. 4 Teuscher A, Berger WG. Awareness of hypoglycaemia in diabetes [letter]. Lancet 1987; 2: 919.
5. 5 Amiel SA. RD Lawrence Lecture 1994. Limits of normality: the mechanisms of hypoglycaemia unawareness Diabetic Med 1994; 11: 918-924.
6. 6 Hepburn DA, Eadington DW, Patrick AW, Colledge NR, Frier BM. Symptomatic awareness of hypoglycaemia: does it change on transfer from animal to human insulin?. Diabetic Med 1989; 6: 586-590.
7. 7 Egger M, Smith GD. Human insulin and hypoglycaemia. Lancet 1992; 340: 301.
8. 8 Brown P. Diabetics not told of insulin risk. The Guardian (9 March) 1999.
9. 9 Airey CM, Williams DRR. Cochrane Collaborative Review Group: Diabetes. Diab Med 1995; 12: 375-376.
10. 10 Chalmers TC, Smith H Jr, Blackburn B, Silverman B, Schroder B, Reitman D et al. A method for assessing the quality of a randomized controlled trial. Controlled Clin Trials 1981; 2: 31-49.
11. 11 Anderson JH, Holcombe JH, Grimes JA, Galloway JA. Hypoglycaemia unawareness and human insulin. Diabetologia 1990; 33: A122.
12. 12 Matyka KA, Maran A, Cranston I et al. Human insulin does not induce de novo changes in the clinical presentation of hypoglycaemia in Type 1 diabetes mellitus. Diabetic Med 1995; 12: S25-S26.
13. 13 George E, Bedford C, Peacey SR, Hardisty CA, Heller SR. Further evidence for a high incidence of nocturnal hypoglycaemia in IDDM. no effect of dose for dose transfer between human and porcine insulins. Diabetic Med 1997; 14: 442-448.
14. 14 Maran A, Lomas J, Archibald H, Macdonald IA, Gale EAM, Amiel SA. Double blind clinical and laboratory study of hypoglycaemia with human and porcine insulin in diabetic patients reporting hypoglycaemia unawareness after transferring to human insulin. Br Med J 1993; 306: 167-171.
15. 15 MacLeod KM, Gold AE, Frier BM. Frequency, severity and symptomatology of hypoglycaemia: a comparative trial of human and porcine insulins in type 1 diabetic patients. Diabetic Med 1995; 12: 134-141.
16. 16 MacLeod KM, Gold AE, Frier BM. A comparative study of responses to acute hypoglycaemia induced by human and porcine insulins in patients with Type 1 diabetes. Diabetic Med, 1996; 13: 346-357.
17. 17 Berger W, Honegger B, Keller U, Jaeggi E. Warning symptoms of hypoglycaemia during treatment with human and porcine insulin in diabetes mellitus. Lancet 1989; i: 1041-1044.
18. 18 Egger M, Davey Smith G, Teuscher AU, Teuscher A. Influence of human insulin on symptoms and awareness of hypoglycaemia: a randomised double blind crossover trial. Br Med J 1991; 303: 622-626.
19. 19 Colagiuri S, Miller JJ, Petocz P. Double-blind crossover comparison of human and animal insulins in patients reporting lack of hypoglycaemia awareness. Lancet 1992; 339: 1432-1435.
20. 20 Lingenfelser T, Overkamp D, Renn W, Gluck H, Maasen M, Eggstein M et al. Different awareness of hypoglycaemia induced by human or purified pork insulin in Type 1 diabetic patients. Diab Res Clin Prac 1991; 13: 29-36.
21. 21 Lingenfelser T, Buettner UW, Plonz C, Steffen J, Eggstein M, Jakober B. Hormonal counterregulation, symptom awareness, and neuro-physiological function in type 1 diabetes during insulin-induced hypoglycaemia. Diabetic Med 1992; 9: 528-535.
22. 22 Bendtson I, Binder C. Counterregulatory hormonal response to insulin-induced hypoglycaemia in insulin-dependent diabetic patients: a comparison of equimolar amounts of porcine and semisynthetic human insulin. J Intern Med 1991; 229: 293-296.
23. 23 Meneilly GS, Milberg WP, Tuokko H. Differential effects of human and animal insulin on the responses to hypoglycaemia in elderly patients with NIDDM. Diabetes 1995; 44: 272-277.
24. 24 Ferrer JP, Esmatjes E, Gonzales-Clemente JM, Goday A, Conget I, Jimenez W et al. Symptomatic and hormonal hypoglycaemic responses to human and porcine insulin in patients with type 1 diabetes mellitus. Diabetic Med 1992; 9: 522-527.
25. 25 Patrick AW, Bodmer CW, Tieszen KL, White MC, Williams G. Human insulin and awareness of acute hypoglycaemic symptoms in insulin-dependent diabetes. Lancet 1991; 338: 528-532.
26. 26 Etti H, Haupt E. Biosynthetisches Humaninsulin. Vergleich der wirkungsprofile von human-NPH-insulin und schweine-NPH-insulin bei Typ 1-diabetikern. Munchener Med Wochenschrift Supplement 1983; 1: S53-S56.
27. 27 Holman RR, Steemson J, Darling P, Reeves WG, Turner RC. Human ultralente insulin. Br Med J 1984; 288: 665-668.
28. 28 Clark AJ, Adeniyi-Jones RO, Knight G, Leiper JM, Wiles PG, Jones RH et al. Biosynthetic human insulin in the treatment of diabetes. A double-blind crossover trial in established diabetic patients. Lancet 1982; ii: 354-357.
29. 29 Storms GE, Lutterman JA, van't Laar A. Efficacy and immunogenicity of human and monocomponent porcine insulin: a randomized double-blind study in diabetic patients previously treated with insulin. Ned J Med 1986; 29: 296-302.
30. 30 Beyer J, Enzmann F, Lauerbach M, Althoff P, Bachman W, Brandsetter K et al. Treatment with human insulin (recombinant DNA) in diabetic subjects pretreated with pork or beef insulin: First results of a multicenter study. Diabetes Care 1982; 5: 140-148.
31. 31 Fletcher JA, Barnett AH, Pyke DA, Volkman HP, Hartog M, Perett AD et al. Transfer from animal insulins to semisynthetic human insulin: a study in four centres. Diabetes Res 1990; 14: 151-158.
32. 32 Gardiner R, Hanna A, Hunt J, Ross S, Tan M. A multicenter open and double-blind study of semi-synthetic human insulin in IDDM patients previously maintained on beef/pork insulin - the Canadian experience. Diabetes 1988; 37: 138A.
33. 33 Greene SA, Smith MA, Cartwright B, Baum JD. Comparison of human versus porcine insulin in treatment of diabetes in children. Br Med J 1983; 287: 1578-1579.
34. 34 Ho L-T, Lam H-C, Wu M-S et al. A twelve month double-blind randomized study of the efficacy and immunogenicity of human and porcine insulins in non-insulin-dependent diabetes. Chin Med J (Taipei) 1991; 47: 313-19.
35. 35 Jacobsen L. A randomised study on long-term side effects in insulin-dependent diabetes with purified porcine versus purified semi-synthetic human insulin. Data on file. Copenhagen: Novo-Nordisk, 1984.
36. 36 Karam J, Brink S, Clements R, Miller L, Raskin P. Evaluation of efficacy and safety of human insulin (Novo) in the treatment of insulin-dependent diabetes mellitus: a double-blind multicentre clinical trial. Diabetes Care 1983; 6: 56-60.
37. 37 Lam H-C, Tang K-T, Wang J-T, Liu Y-F, Wang L-M, Ho L-T. Immunogenicity of monocomponent human and porcine insulin in non-insulin dependent diabetes mellitus. Clin Med J (Taipei) 1988; 41: 217-22.
38. 38 Lam H-C, Ho L-T, Tang K-T e t at. Immunogenicity of highly purified porcine and human insulins in diabetic patients with high titers of insulin antibody. J Formosan Med Assoc 1989; 88: 346-51.
39. 39 Larkins RG, Zajac J, Saunders R, Read A, Hopper JL. A comparative double-blind trial of the effectiveness and antigenicity of semi-synthetic human insulin and purified porcine insulin in newly treated diabetic subjects. Aust NZ J Med 1986; 16: 206-210.
40. 40 Lytken Larsen M, Bjerrum P, Egstrup K. A comparison of semisynthetic human insulin and porcine insulin in the treatment of established diabetes. Danish Med Bulletin 1984; 31: 243-244.
41. 41 Mann NP, Johnston DI, Reeves WG, Murphy MA. Human insulin and porcine insulin in the treatment of diabetic children: comparison of metabolic control and insulin antibody production. Br Med J 1983; 287: 1580-1582.
42. 42 Pedersen C, Hoegholm A. A comparison of semisynthetic human NPH insulin and porcine NPH insulin in the treatment of insulin-dependent diabetes mellitus. Diabetic Med 1987; 4: 304-306.
43. 43 Sonnenberg GE, Chantelau F., Sundermann S, Hauf C, Berger M. Human and porcine regular insulins are equally effective in subcutaneous replacement therapy. Diabetes 1982; 31: 600-602.
44. 44 Fisher BM, Gray CE, Beastall GH, Frier BM. Responses to acute insulin-induced hypoglycaemia in diabetic patients: a comparison of short-acting human and porcine insulins. Diabetes Res 1988; 8: 1-8.
45. 45 Haupt E, Galle M, Oerter E. Symptoms of hypoglycaemia and counterregulatory effects with human and animal insulins. Deutsche Med Wochenschrift 1987; 112: 1209-1212.
46. 46 LeRoith D, Shemer J, Pickens W, Leslie N, Sperling M, Berelowitz M. Comparison of the counterregulatory hormone response to semi-synthetic human insulin and purified porcine insulin in normal subjects and patients with type I diabetes mellitus. Clin Therapeutics 1991; 13: 613-626.
47. 47 Raptis S, Hadjidakis D, Enzmann F, Raptis A, Diamantopoulos E, Rosenthal J. Inhibition of pancreatic glucagon responses to arginine by human insulin (recombinant DNA) and purified porcine insulin in normal and diabetic subjects. Diabetes Care 1982; 5: 93-101.
48. 48 Birtwell AJ, Owens DR, Jones IR, Hayes TM, Beale DJ, el-Shaboury AH et al. Comparison of highly purified semi-synthetic insulin and highly purified porcine insulin in the treatment of type I diabetes: interim report of a multi-centre randomised single blind study. Diabete Metabolism 1984; 10: 295-298.
49. 49 Colagiuri S, Kotowicz MA, Steinbeck AW, Kidson W. Metabolic profiles in diabetic subjects treated with human insulin (Novo) and porcine insulin. Diabetes Care 1983; 6: 49-52.
50. 50 Fernqvist E, Linde B, Ostman J, Gunnarsson R. Effects of physical exercise on insulin absorption in insulin-dependent diabetics. A comparison between human and porcine insulin, Clin Physiol 1986; 6: 489-497.
51. 51 Patrick AW, Collier A, Matthews DM, Macintyre CC, Clarke BF. The importance of the time interval between insulin injection and breakfast in determining postprandial glycaemic control - a comparison between human and porcine insulin. Diabetic Med 1988; 5: 32-35.
52. 52 Richard JL, Rodier M, Cavalie G, Mirouze J, Monnier L. Human (recombinant DNA) and porcine NPH insulins are unequally effective in diabetic patients. A comparative study using continuous blood glucose monitoring. Acta Diabetologica Latina 1984; 21: 211-217.
53. 53 Selam JL, Turner D, Woertz L, Eichner HL, Lauritano A, Charles MA. Comparison of the safety and effectiveness of human and bovine long-acting insulins. Diabetes Res 1989; 12: 131-134.
54. 54 Gomez-Perez FJ, Rojas H, Chacra AR, Obregon O, Suarez-Russi M, Otero JR et al. Insulin transference in 198 patients from 6 Latin American countries [Spanish]. Revista Invest Clinica 1995; 47: 173-179.
55. 55 Marre M, Tabbi-Anneni A, Tabbi-Anneni H, Assan R. Comparative study of NPH human insulin (recombinant DNA) and NPH bovine insulin in diabetic subjects. Diabetes Care 1982; 5: 63-66.
56. 56 Oswald GA, Yudkin JS. A within patient cross over trial of 4 insulin regimens in antibody-negative, C-peptide negative patients. Diabetes Res 1987; 4: 85-89.
57. 57 Sailer D, Volkholz HJ, Pichl J. Blood glucose lowering by human insulins and highly purified porcine insulin. Metabolic study in insulin-injecting diabetics. Fortschritte Med 1985; 103: 527-530.
58. 58 Jovanovic-Peterson L, Kitzmiller JL, Peterson CM. Randomized trial of human versus animal species insulin in diabetic pregnant women: improved glycemic control, not fewer antibodies to insulin, influences birth weight. Am J Obstet Gynecol 1992; 167: 1325-1330.
59. 59 Fankhauser S, von RE. Are there problems in changing diabetic patients from animal to human insulin? Therapeutische Umschau 1990; 47: 41-48.
60. 60 Maassen MM, Lingenfelser T, Gluck H, Renn W, Eggstein M, Jakober B. Cognitive and psychomotor function during hypoglycemia: a comparison between porcine and human insulin. Neuropsychobiology 1990; 24: 30-36.
61. 61 Renner R, Vocke K, Hepp KD. Comparison of the effects of protamine-bound NPH porcine insulin and NPH human insulin in type 1 and 2 diabetes. Deutsche Med Wochenschrift 1986; 111: 1316-1320.
62. 62 Laron Z, Feinmesser P, Albag Y, Ofan R, Karp M. Hypoglycaemia in newly diagnosed diabetic children and adolescents - comparison between human and porcine insulin. Diabetologia 1988; 31: 454.
63. 63 Le Floch JP, Attali JR, Cathelineau G, Lubetzki L, Perlemuter L, Senan C. Changes in the level of anti-insulin antibodies and circulating immune complexes in diabetics treated with human insulin or monocomposed porcine insulin for a year. A multicenter study. Presse Med 1987; 16: 1744-1747.
64. 64 Peacock I, Tattersall RB, Taylor A, Douglas CA, Reeves WG. Effects of new insulins on insulin and C-peptide antibodies, insulin dose, and diabetic control. Lancet 1983; 1: 149-152.
65. 65 Benzi L, Marchetti P, Carriero PL, Ciccarone AM, Di Ganni G, Giannarelli R et al. Long-term therapy with biosynthetic human insulin: importance of short-acting/intermediate-acting insulin ratio on determining efficacy of treatment. Drugs Exp Clin Res 1987; 13: 321-325.
66. 66 Leiper JM, Paterson KR, Lunan CB, MacCuish AC. A comparison of biosynthetic human insulin with porcine insulin in the blood glucose control of diabetic pregnancy. Diabetic Med 1986; 3: 49-51.
67. 67 Schluter KJ, Petersen KG, Kerp L. Clinical experience with human insulin. Deutsche Med Wochenschrift 1982; 107: 10-14.
68. 68 Teuscher A. The biological effect of purely synthetic human insulin in patients with diabetes mellitus [German]. Schweizerische Med Wochenschrift J Suisse Medecine 1979; 19: 743-747.
69. 69 de Beaufort CE, Sodoyez JC, Koch M, Bruining GJ, Sodoyez-Goffaux F. Insulin autoantibodies and immune response to human insulin therapy in 24 type 1 (insulin-dependent) diabetic children: superiority of radio binding assay over solid phase assay. Diabetes Res Clin Prac 1993; 21: 19-24.
70. 70 Zuppinger K, Egger M, Aebi C, Schoenle E, Gschwend-Eigenmann S, Mullis P. Hypoglycemia in children with diabetes treated with human or porcine insulin. German. Schweizerische Med Wochenschrift J Suisse Medecine 1989; 119: 532-535.
71. 71 Kruger DF, Whitehouse FW, Kahkonen DM, Partamian JO, Fachnie JD, Goldman J et al. Experience with biosynthetic human insulin in diabetes. Henry ford Hospital Med Journal 1983; 31: 72-76.
72. 72 Lauritano AA, Clements RSJ, Bell D. Insulin antibodies in non-insulin-dependent diabetes mellitus: effect of treatment with semisynthetic human insulin. Clin Therapeutics 1989; 11: 268-277.
73. 73 Klein BEK, Klein R, Moss SE. Risk of hypoglycemia in users of human insulin. The Wisconsin Fpidemiologic Study of Diabetic Retinopathy. Diabetes Care 1997; 20: 336-339.
74. 74 Orchard TJ, Maser RE, Becker DJ, Dorman JS, Drash AL. Human insulin use and hypoglycaemia: insights from the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetic Med 1991; 8: 469-474.
75. 75 Jefferson IG, Marteau TM, Smith MA, Baum JD. A multiple injection regimen using an insulin injection pen and pre-filled cartridged soluble human insulin in adolescents with diabetes. Diabetic Med 1985; 2: 493-495.
76. 76 Leiper JM, Campbell RR, Curtis LD, Fisher BM, Hunter KR, Knight G et al. Glycaemic control in diabetic patients transferred from therapy with animal insulins to human crystalline zinc insulin of recombinant DNA origin: a multicentre study. Diabetes Res 1987; 4: 1-4.
77. 77 Kahn CB, Lamberton RP, Krauss DS. Transfer from animal to human insulin: a clinical experience. Rhode Island Medicine 1992; 75: 313-315.
78. 78 Schluter KJ, Kerp L. Receptor binding studies and clinical effects of human insulin (recombinant DNA): studies in patients with newly diagnosed type I diabetes, type II diabetes, insulin resistance (type A and type B), insulin antibodies, insulin allergy, and 'brittle' diabetes. Diabetes Care 1982; 5: 152-160.
79. 79 Raskin P, Etzwiler DD, Davidson JK, Nolte M, Stephens JW, MacGillivray M et al. Rapid decrease of insulin-specific IgG antibody levels in insulin-dependent patients transferred to semisynthetic human insulin. Diabetes Res 1987; 6: 123-128.
80. 80 Breidahl HD. Human insulin [letter; comment]. Med J Australia 1991; 154: 493-494.
81. 81 Moses RG. Human insulins [letter]. Med J Australia 1991; 154: 364.
82. 82 Stocks AE. Human insulin [letter]. Med J Australia 1991; 154: 295-296.
83. 83 Egstrup K, Olsen J. Treatment with human insulin in out patient diabetics [letter]. Lancet 1982; 2: 222-223.
84. 84 Berger WG, Althaus BU. Reduced awareness of hypoglycemia after changing from porcine to human insulin in IDDM [letter]. Diabetes Care 1987; 10: 260-261.
85. 85 Sachse G, Maser E, Federlin K. Long-term therapy with human insulin. Clinical experiences. Deutsche Med Wochenschrift 1985; 110: 403-406.
86. 86 Gadia M, Sosenko JM, Salzman R, Lauritano AA, Haycock P. NPH human insulin: does it work in a once-a-day regimen? Clin Therapeutics 1989; 11: 120-128.
87. 87 Vitacolonna E, Consoli A, Capani F. Semisynthetic human insulin in the treatment of diabetes type I. Preliminary experience [Italian]. Ballettino - Societa Italiana Biologia Sperimentale 1984; 60: 1849-1852.
88. 88 Virgili F, Frigato F, Magnanini PG, Coronel GA, Iavicoli M. Reduction in insulin antibodies 42 months after transfer from porcine to human monocomponent insulins. Diabetes Res 1988; 9: 19-20.
89. 89 Teuscher A, Berger WG. Hypoglycaemia unawareness in diabetics transferred from beef/porcine insulin to human insulin. Lancet 1987; 2: 382-385.
90. 90 Lyngsoe J, Vestermark S. The efficacy and safety of human insulin (Novo) in insulin-dependent diabetic patients. Diabetes Care 1983; 6: 53-55.
91. 91 Balabolkin MI, Poliakova IA, Mamaeva GG. Use of domestic human insulin in patients with type I diabetes mellitus [Russian]. Problemy Endokrinologii 1993; 39: 13-14.
92. 92 Hosl W, Kloss G, Buchel CG. Experiences wich human insulin. Results of a study in 1267 diabetics previously treated with animal insulin. Fortschritte der Medizin 1986; 104: 721-724.
93. 93 Egstrup K, Andersen P. Long-term treatment with semisynthetic human insulin. Ugeskrift for Laeger 1983; 145: 3252-3254.
94. 94 Teuscher A, Egger M. Human insulin hypoglycaemia unawareness [letter]. Lancet 1989; 1: 1072.
95. 95 von Kriegstein E. Human insulin and hypoglycaemia. Lancet 1992; 340: 302.
96. 96 Stephenson J, Fuller J. Hypoglycaemia as cause of death in human insulin era [letter]. Lancet 1990; 335: 661.
97. 97 Borch-Johnsen K, Helweg-Larsen K. Sudden death and human insulin: is there a link? Diabetic Med 1993; 10: 255-259.
98. 98 Heine RJ, van dVA. Human insulin and hypoglycaemia [letter]. Lancet 1990; 335: 62.
99. 99 Gorden P. Human insulin and hypoglycemia [letter]. N Engl J Med 1990; 322: 1007-1008.
100. 100 Anonymous. Epidemiology of severe hypoglycemia in the diabetes control and complications trial. The DCCT Research Group. Am J Medicine 1991; 90: 450-459.
101. 101 Egger M, Smith GD, Imhoof H, Teuscher A. Risk of severe hypoglycaemia in insulin treated diabetic patients transferred to human insulin: a case control study [see comments]. Br Med J 1991; 303: 617-621.
102. 102 Jick H, Hall GC, Dean AD, Jick SS, Derby LE. A comparison of the risk of hypoglycemia between users of human and animal insulins. 1. Experience in the United Kingdom. Pharmacotherapy 1990; 10: 395-397.
103. 103 Jick SS, Derby LE, Gross KM, Jick H. Hospitalizations because of hypoglycemia in users of animal and human insulins. 2. Experience in the United States. Pharmacotherapy 1990; 10: 398-399.
104. 104 Ganz MA, Unterman T, Roberts M, Uy R, Sahgal S, Samter M et al. Resistance and allergy to recombinant human insulin. J Allergy Clin Immunol 1990; 86: 45-51.
105. 105 Berke L, Owen JAJ, Atkinson RLJ. Allergies to human insulin [letter]. Diabetes Care 1984; 7: 402-403.
106. 106 Barham P. Patient's choice of animal or human insulin [letter]. Lancet 1988; 2: 1019-1020.
107. 107 Bell DS. Failure to recognise hyperglycaemia may be a problem associated with insulin manufactured by the recombinant DNA method (letter). Clin Therapeutics 1989; 11: 707-708.
108. 108 Burden AC. Awareness of hypoglycaemia in diabetes [letter]. Lancet 1987; 2: 1267.
109. 109 Burden AC. Increased hypoglycaemia on insulin derived from yeast [letter]. Lancet 1990; 335: 485.
110. 110 Daneman D, Zinman B. Syndrome of hypoglycemia unawareness when changing insulin species [letter]. Diabetes Care 1991; 14: 145-146.
111. 111 Kerr D, Macdonald I, Hillier J, Tattersall R. Adrenaline response to hypoglycaemia and insulin species [letter]. Lancet 1989; 1: 836.
112. 112 Sadler C. A change for the worse? Nursing Times 1991; 87: 16-17.
113. 113 Tattersall RB, Gill GV. Unexplained deaths of type 1 diabetic patients. Diabetic Med 1991; 8: 49-58.
114. 114 Turner TA, O'Mullane NM, Sivner A, Healey M, Walter D. Switching to human insulin [letter]. Lancet 1988; 2: 1150.
115. 115 Altman JJ, Feldman S, Bonnemairie M, Elian N, Squiban P. No increase of hypoglycaemia upon transfer of aged longstanding type 1 diabetic patients to human insulin: a prospective randomized study. The Investigators of the Transfert Study. Diabet Metabol 1999; 24 : 419-423.
116. 116 Altman JJ, Elian N, Bonnemairie M, Calmar S, Feldman S. Safety of human insulin in poor-sighted elderly diabetic patients. Diabetes Care 1999; 22: 2089.